Most cases are subclinical, but given the newness of the therapy, it’s necessary to keep tabs on the issue going forward.

The results suggest toxicity may not be as pervasive as previously thought, which argues for more-personalized monitoring.

However, acquired hospitals may be inappropriately selecting patients and doing more profitable cardiac caths.